Detalhe da pesquisa
1.
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
Lancet
; 399(10323): 461-472, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065705
2.
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Vaccine
; 41(11): 1875-1884, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36781334
3.
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Hum Vaccin Immunother
; 19(1): 2206359, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37226504
4.
Evaluation of serotonin-2A receptor occupancy with 123I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone administration in the canine brain.
Nucl Med Commun
; 29(8): 724-9, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18753826